The lead applicant and point of contact must be based in an academic/research institution, either in the UK or abroad. Co-applicants from small and medium enterprises are permitted.
If the project requires ethical approval and/or Home Office licences or equivalent, the award is dependent upon the requisite approvals being granted.
The Lead applicant is expected to have a contract (fixed term or tenure) which covers the proposed duration of the grant. If the Lead applicant does not hold a tenure appointment, the application must include a co-applicant that does.
Applicants seeking to obtain preliminary data before a collaboration with one or more of ARUK’s Drug Discovery Institutes are required to hold early discussions with either one of the DDI Chief Scientific Officers (CSOs) regarding the suitability of the target and the data that is necessary to obtain before further work is initiated. A letter of support for the TVPG work plan will be required of the collaborating DDI CSO(s) with the application.
Applicants aiming to gain preliminary data to support an Expression of Interest submission to the Dementia Consortium are not required to obtain a letter of support from Evotec. However, applicants will be asked to justify how the outcomes of their proposals would fit within the remit of a future Dementia Consortium project.
TVPG applications will be viewed favourably if they follow a rejection from a prior Dementia Consortium submission where the feedback encouraged further experimental work to support their proposal. In such cases, the Consortium feedback will explicitly suggest applying for a TVPG to address the points raised and this feedback should be cited in the TVPG submission.
This scheme is not designed to cover:
- Pilot projects with no translational endpoint that could be taken up by one of ARUK’s regular grant schemes
- Bridging funds for staff between posts/funding (ARUK Network members can apply to Network Support grants)
- Extensions of current ARUK project grants (ARUK Major Project grant holders can apply to Extension grants).
Clinical trials and add-ons should be applied for through the Global Clinical Trials Fund. Drug discovery and development work should be applied for through the Dementia Consortium or through ARUK’s Drug Discovery Institutes.
See our Eligibility Guidelines for further information.
Applications are made via our grant application website.
Grant schemes only appear on this website when the round is open and we are accepting new applications.
View an example Target Validation Pathfinder Grant application form.
Alzheimer’s Research UK is a member of the Association of Medical Research Charities and follows their guidelines for best practice in peer review. Grants are awarded entirely on scientific merit in relation to Alzheimer’s Research UK’s remit and on the basis of open competition. The quality of the application and applicants is the key determinant of outcome, although the strength of the dementia research environment within the institution is also considered.
For applications reviewed at GRB meetings:
Discussion in meeting
Each application is allocated to two GRB members, based roughly on their areas of expertise. The two members will present the application to the rest of the Board, including any relevant information from external reviews or applicant responses. A short discussion will follow before the GRB score the application. Applications for each grant scheme are ranked by their average score and recommendations for funding are made.
Those applications recommended for funding by the GRB are presented to the Trustees for final approval.
For applications reviewed outside of GRB meeting:
All GRB members are asked to read the application and associated documents and give a yes/no decision for whether or not the application should be funded giving comments.
A subgroup of the GRB hold a teleconference to discuss the application and the comments raised and a decision is reached.
Those applications recommended for funding by the GRB are presented to the trustees for final approval.
In the last three years Alzheimer’s Research UK has received 20 applications for Target Validation Pathfinder Grants. 8 of these projects were awarded funding.
The terms and conditions of grant differ for each grant scheme and contracts are drawn up individually once the grants have been awarded.
All grant holders are expected to report on the progress of their project on a regular basis. Read more about our reporting requirements on the measuring impact page.
Download our GDPR statement that explains how Alzheimer’s Research UK Research Team handles personal data about our grant applications and the rights that applicants have under data protection law. In this Notice, we refer to this type of information as “Applicant Data”.
This statement applies to applications submitted via Grant Tracker. It also applies to applications summitted via other means, such as by post and email.
Download GDPR statement